NASDAQ: NRIXNurix Therapeutics Inc Stock
$17.07+0.03 (+0.18%)
Updated Jun 16, 2026
NRIX Price
$17.07
Fair Value Price
N/A
Market Cap
$1.77B
52 Week Low
$8.20
52 Week High
$22.50
P/E
-5.38x
P/B
3.67x
P/S
24.49x
PEG
N/A
Dividend Yield
N/A
Revenue
$71.78M
Earnings
-$295.28M
Gross Margin
100%
Operating Margin
-410.31%
Profit Margin
-411.4%
Debt to Equity
0.32
Operating Cash Flow
-$260M
Beta
1.57
Next Earnings
Jul 9, 2026
Ex-Dividend
N/A
Next Dividend
N/A
NRIX Overview
Nurix Therapeutics, Inc., a biopharmaceutical firm headquartered in San Francisco, California, was founded in 2009. This company, which rebranded from Nurix Inc. in October 2018, is dedicated to the identification, advancement, and commercialization of innovative small molecule treatments for various cancers and immune system disorders. Its robust pipeline features several key drug candidates: NX-2127 and NX-5948: Both are orally administered Bruton's tyrosine kinase (BTK) degraders, targeting B-cell malignancies that have relapsed or are resistant to prior therapies. NX-5948 is also being explored for autoimmune conditions. NX-1607: An orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, developed for immuno-oncology applications. NX-0255: A CBL-B inhibitor designed for ex vivo use to enhance the efficacy of adoptive T-cell therapies. DeTIL-0255: Currently undergoing Phase 1 clinical trials for gynecological cancers, including ovarian, endometrial, and cervical cancers. To further its mission, Nurix has forged significant strategic alliances, notably with Gilead Sciences, Inc. for the development of therapies addressing cancer and other challenging diseases, and also with Sanofi S.A.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine NRIX's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
NRIX
Ranked#448 of 462
Ranked#448 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $226.88 | A | |
| $52.10 | A | |
| $16.22 | A |
Be the first to know about important NRIX news, forecast changes, insider trades & much more!
NRIX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NRIX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NRIX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
NRIX is good value based on its book value relative to its share price (3.67x), compared to the US Biotechnology industry average (4.86x)
P/B vs Industry Valuation
NRIX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more NRIX due diligence checks available for Premium users.
Valuation
NRIX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-5.38x
Industry
16.03x
Market
13.25x
NRIX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.67x
Industry
4.86x
NRIX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NRIX's financial health
Profit margin
Revenue
$6.3M
Net Income
-$87.2M
Profit Margin
-1,394.3%
NRIX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
NRIX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$636.1M
Liabilities
$155.2M
Debt to equity
0.32
NRIX's short-term assets ($554.39M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NRIX's short-term assets ($554.39M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NRIX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
NRIX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$71.9M
Investing
-$123.8M
Financing
$20.0M
NRIX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NRIX vs Biotech Stocks
Nurix Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.